Application of elsholtzia volatile oil in resisting novel coronavirus
The volatile oil extracted by steam distillation, as an inhibitor of 3CL and PLP, solved the problem of treatment of acute lung injury of SARS-CoV-2, and demonstrated its significant inhibitory effect and potential market in the fight against novel coronavirus value.
Patent Information
- Application Number
- CN202411166435.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-23
AI Technical Summary
Existing anti-novel coronavirus drugs have not yet effectively utilized the antiviral potential of volatile oils of volatilated thorns, especially the inhibitory effect of SARS-CoV-2 on 3CLpro and PLP proteins has not been fully studied and applied.
The dry above-ground part of the saccharin is extracted by steam distillation to obtain saccharin with the main components of trans caryophyllene, α-caryophyllene, palmitoleic acid, caryophyllene oxide, α-pinene, isoperone epoxide, obtained saccharin with the main components of trans caryophyllene, α-caryophyllene, and isoperone epoxide. Volatile oil and use it as an inhibitor of 3CL and PLP for anti-SARS-CoV-2-induced acute lung injury.
The volatile oil of sars has a significant inhibitory effect on the 3CLpro and PLP of SARS-CoV-2, which can reduce acute lung injury caused by N protein, and shows high safety and strong efficacy, and has huge market potential.
Smart Images

Figure CN119015339A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of traditional Chinese medicine, and specifically relates to an application of Elsholtzia volatile oil in resisting the new coronavirus. Background Art
[0002] The disclosure of this background information is intended to enhance understanding of the general background of the invention and should not necessarily be taken as an acknowledgment or any form of suggestion that this information constitutes the prior art already known to a person skilled in the art.
[0003] In recent years, respiratory infectious diseases have seriously endangered people's health and brought major public safety issues, especially the new coronavirus in 2019. Coronavirus is a common type of RNA virus in nature. It is widely distributed and easy to mutate. For a long time, coronavirus has been considered an important pathogen that causes respiratory and gastrointestinal lesions in mammals and birds. It is contagious to humans and can cause diseases such as colds and pneumonia. The Coronaviridae family can be classified into four genera: α, β, γ and δ, of which seven species have infection risks to humans. HCoV-229E, HCoV-HKU1, HCoV-NL63 and HCoV-OC43 are widely distributed in the population. They are generally less toxic and have mild symptoms after infection, similar to colds. The other three (SARS-CoV, MERS-CoV and SARS-CoV-2) are highly harmful, with strong infectivity, high mortality and wide prevalence. They can cause serious respiratory diseases. Patients with severe symptoms will suffer from lung failure or even death.
[0004] In the past two decades, there have been three major coronavirus outbreaks, namely SARS-CoV in 2002, MERS in 2012, and SARS-CoV-2 in 2019. SARS-CoV and MERS-CoV can cause symptoms such as fever, dry cough, headache, dyspnea, lower respiratory tract infection, lymphocytopenia and diarrhea, and even death in severe cases. However, they are less contagious and have a shorter incubation period than SARS-CoV-2. According to statistics from the World Health Organization, as of 2024, SARS-CoV-2 has caused more than 770 million confirmed cases worldwide, leading to a serious public health crisis and widespread health damage. Its typical clinical symptoms are fever, dry cough, fatigue, and shortness of breath. In severe cases, it can develop into acute respiratory distress syndrome (ARDS), acute lung injury, septic shock, and even death.
[0005] SARS coronavirus mainly encodes two proteases, including 3C-like protease (3CLpro) and papaya-like cysteine protease (PLpro). Both play a vital role in viral replication and infection mechanisms, so inhibiting these two enzymes can effectively inhibit SARS coronavirus and is also an important target for the discovery of anti-coronavirus drugs.
[0006] Finding potential antiviral drugs or lead compounds with low toxicity and side effects from natural plants is one of the important directions of antiviral research. Mosla chinensis Maxim) or Elsholtzia jiangensis ( Mosla chinensis 'Jiangxiangru') is a Chinese medicine for both medicine and food. Elsholtzia is warm in nature and pungent in taste. It has the effects of sweating, dispelling dampness and harmonizing the middle. It is commonly used in the treatment of summer heat cold, aversion to cold and fever, headache without sweating, abdominal pain, vomiting and diarrhea. CN111494456A discloses the use of an aqueous extract of Elsholtzia in the preparation of anti-new coronavirus drugs. However, Elsholtzia and Elsholtzia jiang are mainly produced in Guangdong, Guangxi, Fujian, Hunan, Zhejiang, Jiangxi and other places, and the northern Elsholtzia is Elsholtzia costus. There is no research report on the volatile oil of Elsholtzia costus against the new coronavirus. Summary of the invention
[0007] The present invention provides an application of Elsholtzia ciliata volatile oil in resisting the novel coronavirus.
[0008] To achieve the above purpose, the present invention adopts the following technical solution.
[0009] Application of Elsholtzia ciliata volatile oil in preparing anti-coronavirus drugs.
[0010] The coronavirus is human coronavirus (HCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
[0011] The virus is SARS-CoV-2.
[0012] The application is as a 3CL and PLP protein inhibitor or to alleviate acute lung injury caused by SARS-CoV-2.
[0013] The volatile oil of Elsholtzia ciliata is Elsholtzia stauntoni Benth) by steam distillation.
[0014] The main components of the Elsholtzia volatile oil are trans-caryophyllene, α-caryophyllene, palmitoleic acid, caryophyllene oxide, α-pinene, Δ-cadinene, and iso-cadinene epoxide, and the content of the main components is greater than 90wt%; the content of trans-caryophyllene is 65wt%-70wt%, and the content of α-caryophyllene is 8wt%-12wt%.
[0015] The present invention has the following advantages: The present invention provides an application of volatile oil of Elsholtzia in anti-coronavirus. The volatile oil of Elsholtzia has the characteristics of high safety, strong efficacy, convenient administration, etc., and has an inhibitory effect on both 3CLpro and PLP proteins of SARS-CoV-2, and can reduce acute lung injury caused by N protein. The volatile oil of Elsholtzia can be prepared into various application forms and used in antiviral products, and has huge market potential. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is the total ion current diagram of Elsholtzia oil; Figure 2 The following are the fitting diagrams of the inhibition rates of different concentrations of Elsholtzia oil on PLP (A) and 3CLpro (B); Figure 3 This is the fitting diagram of the inhibition rate of different concentrations of Elsholtzia oil on HCoV-229E; Figure 4 is the mRNA expression of inflammatory factors in cells under different treatments; Figure 5 Lung function of mice treated differently; Figure 6 The mRNA expression levels of inflammatory factors in lung tissue of mice treated with different methods. DETAILED DESCRIPTION
[0017] The present invention will be further described below in conjunction with embodiments and drawings, but the present invention is not limited by the following embodiments.
[0018] Example 1 Inhibition of 3C-like protease (3CL) and papain-like protease (PLP) by Elsholtzia oil 1. Preparation of 3CLpro and PLP proteins According to the records in the article "Inhibitory Effects of 6 Traditional Chinese Medicines on the Activity of SARS-CoV-2 3CLpro and PLP" (2023), recombinant plasmids pGEX-6P-1-SARS-CoV-2-3CL and pET-32a (+) -SARS-CoV-2-PLP were obtained. After the recombinant plasmids were transformed into BL21 competent cells, recombinant Escherichia coli was obtained to express the two proteins. The recombinant bacteria were cultured and induced with IPTG, and the cell lysate was purified using HisTrap HP affinity chromatography column to obtain SARS-CoV-2 3CL and PLP proteins.
[0019] 2. Drug and ingredient analysis Elsholtzia oil (purity: 98%, Chinese Pharmacopoeia 2020 edition 2204 Volatile Oil Determination Method A) was purchased from Jiangxi Hengcheng Natural Spice Oil Co., Ltd. (Batch No.: 20220620) and extracted by steam distillation of Elsholtzia.
[0020] (1) Sample processing Take 10 μL of Elsholtzia oil and place it in a 2 mL EP tube, add 990 μL of ethyl acetate, and mix by ultrasonic. Use a 1 mL disposable syringe to draw it and pass it through a 0.45 μm microporous organic filter membrane into the injection bottle, which is the sample solution to be tested.
[0021] (2) Analysis conditions The chromatographic column was an HP-5MS column (30 m× 0.25 mm× 0.25 μm); the carrier gas was high-purity helium with a flow rate of 1 mL / min, split injection, a split ratio of 50:1, an injection volume of 1.0 μL, and a programmed temperature increase (initial 70°C, rate 10°C / min to 100°C, 3°C / min to 160°C, 5°C / min to 190°C, and retention for 1 min).
[0022] Mass spectrometry conditions: EI ion source, ion source temperature 230 °C, ionization energy 70 eV, mass scan range m / z 12-550.
[0023] (3) Results The total ion current is shown in Figure 1 The area normalization method was used to calculate the percentage of each integrated chromatographic peak in the total peak area, and then the mass spectrum data of the components of Elsholtzia oil obtained by GC-MS were analyzed by using NIST 2.3 spectral library retrieval and automatic deconvolution technology.
[0024] Table 1 Identification results of the main chemical components of Elsholtzia oil A total of 51 components were isolated from Elsholtzia oil, 26 of which were identified, as shown in Table 1, accounting for 98% of the total peak area. Among them, trans-caryophyllene, α-caryophyllene, palmitoleic acid, caryophyllene oxide, α-pinene, Δ-cadinene, and iso-cadinene epoxide were all greater than 1%, which were the main components and accounted for 92.24% of the total peak area.
[0025] 2. IC of Elsholtzia oil on 3CLpro and PLP 50 Elsholtzia oil was diluted with DMSO starting from 100 μg / mL to form a series of solutions, and ebselen or GRL0617 was diluted with DMSO starting from 1.000 μmol / L and 50.000 μmol / L to form a series of solutions. The inhibition rate and IC of 3CLpro and PLP were determined according to the following method: 50 : In a 96-well plate with a transparent bottom, 3CLpro or PLP (40 μL / well, final concentration 100 nmol / L) was mixed with Elsholtzia oil (10 μL / well), Ebselen (10 μL / well) or GRL0617 (10 μL / well), incubated at room temperature for 30 min, and then 3CLpro or PLP fluorescent substrate (50 μL / well, final concentration 25 nmol / L or 30 nmol / L) was added. The fluorescence intensity was immediately detected using a multifunctional microplate reader. The detection conditions were gain value 100, room temperature, excitation light 336 nm (3CLpro), 360 nm (PLP), emission light 490 nm, detection interval 30 s, and total detection time 60 min. The drug inhibition rate was calculated based on the increase in fluorescence intensity of different drugs after 1 h of reaction, and the formula was: Inhibition rate = ×100%; The IC values of 3CLpro and PLP were fitted according to the inhibition rates at different concentrations. 50 .
[0026] The fitting curve is as follows Figure 2 As shown, the IC of Elsholtzia oil on 3CLpro 50 The IC value of ebselen for 3CLpro was (45.05± 3.78) μg / mL. 50 The IC value of Elsholtzia oil on PLP was (29.34± 1.65) μg / L. 50 The IC value of GRL0617 for PLP is (8.002± 1.395) μg / mL. 50 The above results show that Elsholtzia oil has an inhibitory effect on both 3CLpro and PLP, and its inhibitory effect on PLP is stronger.
[0027] Example 2 Effect of Elsholtzia oil against HCoV-229E in vitro HCoV-229E was purchased commercially for the experiment and dissolved in DMSO to the maximum solubility concentration. The cell maintenance medium was doubled to obtain the test solutions of 6 volatile components of traditional Chinese medicine including the maximum solubility. Huh-7 cells (1.5×10 5 / well), placed in a 37℃, 5% CO2 cell culture incubator for 24 h, and discarded the culture medium. Add 500 µL of the test solution to each well, discard the culture medium after 4 h, add 500 µL of HCoV-229E virus dilution (MOI=0.1, dilute the virus with the test solution) to each well, continue to act for 1 h, discard the culture medium, and add 500 μL of the test solution to each well. At the same time, set up a virus control well without drug effect. After culturing in a 34℃, 5% CO2 cell culture incubator for 48 h, freeze and thaw three times, centrifuge in a low-temperature high-speed centrifuge, and store the virus supernatant in an ultra-low temperature refrigerator at -80℃.
[0028] The TCID of the collected supernatant was determined by CCK8 method and Reed-Muench method. 50 According to TCID 50 The results calculated the efficacy, that is, the inhibition rate of Elsholtzia oil against HCoV-229E, and the formula was as follows: Inhibition rate = ×100%; Starting from the highest final concentration of 50 μg / mL, six gradients of 2-fold dilution were performed. Each concentration of the drug was tested according to the above method, and the results were fitted to obtain the IC 50 .
[0029] The fitting diagram of Elsholtzia oil to HCoV-229E is shown in the figure Figure 3 Shown: IC 50 It is 1.602±0.597 μg / mL.
[0030] Example 3 Effect of Elsholtzia oil on N protein pathology and inflammation in vitro 1. Obtaining N protein The SARS-CoV-2 N protein recombinant plasmid pET28A-SARS-CoV-2-N plasmid was designed based on the plasmid pET-32a(+)-N-protein donated by Professor Tao Shengce of Shanghai Jiao Tong University. After transformation into BL21 competent cells, endotoxin was removed after induction purification and stored in aliquots. Polymyxin B (250 μg / mL) was added before the experiment and incubated in a 37°C biochemical incubator for 1 h to ensure that there was no endotoxin interference with the experiment.
[0031] 2. Protective effect of Elsholtzia oil on N protein-induced cytopathic effects Human lung epithelial cell line BEAS-2B (B2B) was cultured according to the standard procedure in the instruction manual and used in the experiment: B2B cells were expressed at 1.6×10 5The cells were plated in a 96-well plate at a concentration of 0.1 μg / mL and placed back in a 37°C, 5% CO2 cell culture incubator for culture. After 6 h of plating, the original culture medium was discarded, the cells were rinsed with PBS, and serum-free DMEM was added for starvation culture overnight. Elsholtzia oil group (cell-grade DMSO dissolved, final concentration 0.1 μg / mL), blank control group, and model group (N protein + 0.1% DMSO) were set up to detect OD 450 , the protection rate is calculated according to the following formula: Protection rate = ×100%.
[0032] The protection rate of Elsholtzia oil against N protein-induced cytopathic effects was 31.61±3.347.
[0033] 3. Effect of Elsholtzia oil on cellular inflammation induced by N protein B2B cells were expressed at 1.6×10 5 The cells were plated in a 96-well plate at a concentration of 0.1 μg / mL and placed back in a 37°C, 5% CO2 cell culture incubator for continued culture. After 6 h of plating, the original culture medium was discarded, the cells were rinsed with PBS, and serum-free DMEM was added for starvation culture overnight. An Elsholtzia oil group (final concentration 0.1 μg / mL), a blank control group, and a model group were set up to detect the mRNA expression of inflammatory factors IL-6, IL-8, IL-18, IL-1β, and TNF-α.
[0034] The results are as follows Figure 4 As shown: Elsholtzia oil has a tendency to downregulate the secretion of cellular inflammatory factors caused by N protein.
[0035] Example 4 Effect of Elsholtzia oil on acute lung injury in mice induced by N protein SPF grade C57BL / 6JNifdc male mice, four weeks old, weighing 17-19 g, batch number 110011231110791025, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. [SCXK (Beijing) 2022-0006]. During the feeding period, the mice were free to eat and drink, the light cycle was 12 h, the room temperature was maintained at 22-25℃, and the humidity was 40%-60%. They were randomly divided into 3 groups, 3 mice in each group, normal group, Elsholtzia oil group, and model group.
[0036] After intraperitoneal injection of 150 μL 1% sodium pentobarbital for anesthesia, the drug group was nebulized with 25 μL 1% Elsholtzia oil every day, and the model group was nebulized with 25 μL normal saline, pre-medication for 3 days. On the third day, 50 μL (60 μg) N protein was instilled intraperitoneally to stimulate the drug group and the model group. Lung function was tested immediately 24 hours after N protein stimulation, and the mice were killed, and the lungs, spleens, and thymus were weighed to calculate the organ index. The lung tissues were retained to detect the relative expression of mRNA of inflammatory factors IL-6, IL-1β, IFN-γ, and TNF-α.
[0037] Mouse lung function Figure 5 As shown, after N protein stimulation, respiratory rate, tidal volume, minute ventilation, cumulative volume, maximum expiratory flow rate, maximum inspiratory flow rate, relative time, and Penh were significantly upregulated, while inspiratory time and expiratory time were significantly downregulated. Treatment with Elsholtzia oil can significantly adjust the respiratory function status of mice and restore it to a level that is no different from that of the normal group.
[0038] After the mice were dissected, there were no significant differences in the organ indexes.
[0039] Expression of inflammatory factor mRNA in lung tissue Figure 6 As shown: Elsholtzia oil can downregulate the relative expression of four inflammatory factors: IL-6, IL-1β, IFN-γ, and TNF-α.
[0040] The above results indicate that Elsholtzia oil can resist N protein-induced acute lung injury in mice.
Claims
1. Application of Elsholtzia ciliata volatile oil in the preparation of anti-coronavirus drugs.
2. The use according to claim 1, It is characterized in that The volatile oil of Elsholtzia ciliata is Elsholtzia stauntoni Benth) by steam distillation.
3. The use according to claim 1, It is characterized in that The main components of the Elsholtzia volatile oil are trans-caryophyllene, α-caryophyllene, palmitoleic acid, caryophyllene oxide, α-pinene, Δ-cadinene, and iso-cadinene epoxide, and the content of the main components is greater than 90wt%; the content of trans-caryophyllene is 65wt%-70wt%, and the content of α-caryophyllene is 8wt%-12wt%.
4. The use according to claim 1, It is characterized in that The main components of the Elsholtzia volatile oil are trans-caryophyllene, α-caryophyllene, palmitoleic acid, caryophyllene oxide, α-pinene and isocaryophyllene epoxide, and the content of the main components is greater than 90%.
5. The use according to claim 1, It is characterized in that The coronavirus is HCoV or SARS-CoV-2.
6. The use according to claim 1, It is characterized in that The coronavirus is SARS-CoV-2.
7. The use according to claim 1, It is characterized in that The application is as a 3CL and PLP protein inhibitor or to alleviate acute lung injury caused by SARS-CoV-2 N protein.
Citation Information
Patent Citations
Traditional Chinese medicine composition with prevention and treatment of viral diseases and application of traditional Chinese medicine composition
CN111150755A
Application of Mosla chinensis Maxim water extract in preparation of anti-novel coronavirus drugs
CN111494456A
Traditional Chinese medicine for preventing novel coronavirus pneumonia, preparation process of traditional Chinese medicine, and traditional Chinese medicine beverage
CN112516276A
Preparation of Elsholtzia ciliata volatile oil at different parts and detection of chemical components
CN113773907A
Composition for preventing and treating coronavirus infection
CN113855654A
